The effect of pr-er, p53 biomarkers on prognosis of breast cancer

As the most common cancer with a specific location and the cause of death causes it in women.Nowadays, to facilitate the work of estimating and predicting the consequences of breast cancer patients, and thus the rate of response to treatment in them, we decided to Investigate several factors called prognostic factors and determinants for this policy. Prognostic factors are typically tissue molecular markers that can be used to estimate life-free survival and overall patient health. Among these most important factors are estrogen receptors (ER), progesterone receptors (PRs) ) And P53. Generally, these tumor agents are markers or biomarkers that are often proteinuria in the individual s serum or urine and are produced by the tumor or the body itself in response to cancer stimuli, the most important of which are Cancer Antigen 27.29 Cancer Antigen 15.3, PR and ER . All of which are glycoprotein, and ketopicin D acts as a growth factor for estrogen activity as an agent for growth through insulin receptor and is suitable for prognosis in terms of tumor invasion and metastasis (CEA), (CA 15.3) Molecular glycoproteins are high molecular masses that accumulate in the vicinity of the glandular glands and are detected by 2 antibodies P8 and P3 115. In the treatment process, many cancers use these biomarkers as a measure of return prediction. In this regard, in breast cancer, the simultaneous use of tools and clinical examination methods can have a two-component effect on prognosis

Keywords:

Breast Cancer , Cancer Diagnosis , Cancer Prevention , Cell and Cancer , Cancer Genetics , Cancer Treatment and Management